Impact of Brokerage Rating on Abeona Therapeutics Inc.(ABEO)

Many Abeona Therapeutics Inc.(ABEO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Abeona Therapeutics Inc was Initiated by Jefferies to Buy on Jan 6, 2017.

Company has reported several Insider transactions to the SEC, on Sep 28, 2016, Todd Wider (director) purchased 5,000 shares at 5.48 per share price.On Aug 3, 2015, Mark J Ahn (director) purchased 18,182 shares at 5.50 per share price.

Abeona Therapeutics Inc. (NASDAQ:ABEO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 5 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys.

Abeona Therapeutics Inc. (NASDAQ:ABEO): According to 5 Analysts, The short term target price has been estimated at $ 16.2.The target price could deviate by a maximum of $4.21 from the forecast price. In the near term, the target price could hit a high of $21 and a low of $ 11.

Abeona Therapeutics Inc. (NASDAQ:ABEO) rose 5.77% or 0.3 points on Tuesday and made its way into the gainers of the day. After trading began at $5.25 the stock was seen hitting $5.675 as a peak level and $5.2 as the lowest level. The stock ended up at $5.5. The daily volume was measured at 716,943 shares. The 52-week high of the share price is $9.44 and the 52-week low is $2.05. The company has a market cap of $220 million.

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

Abeona

Share this post

Post Comment